1. Home
  2. BWA vs MRNA Comparison

BWA vs MRNA Comparison

Compare BWA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BorgWarner Inc.

BWA

BorgWarner Inc.

N/A

Current Price

$53.21

Market Cap

10.9B

ML Signal

N/A

Logo Moderna Inc.

MRNA

Moderna Inc.

N/A

Current Price

$55.54

Market Cap

11.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BWA
MRNA
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
11.5B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
BWA
MRNA
Price
$53.21
$55.54
Analyst Decision
Buy
Hold
Analyst Count
15
12
Target Price
$57.60
$33.00
AVG Volume (30 Days)
4.2M
9.6M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
1.31%
N/A
EPS Growth
N/A
21.77
EPS
1.28
N/A
Revenue
$14,316,000,000.00
$19,263,000,000.00
Revenue This Year
$0.54
$8.28
Revenue Next Year
$4.85
$16.53
P/E Ratio
$40.24
N/A
Revenue Growth
1.63
4.29
52 Week Low
$24.40
$22.28
52 Week High
$70.08
$59.55

Technical Indicators

Market Signals
Indicator
BWA
MRNA
Relative Strength Index (RSI) 44.97 63.68
Support Level $41.46 $23.74
Resistance Level $70.08 N/A
Average True Range (ATR) 1.79 3.84
MACD -1.24 0.26
Stochastic Oscillator 18.45 69.97

Price Performance

Historical Comparison
BWA
MRNA

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: